Excessive or inappropriate use of non-steroidal anti-inflammatory drugs can affect cardiovascular and renal function. Non-steroidal anti-inflammatory drugs, both non-selective and selective cyclooxygenase 2 inhibitors, are among the most widely used drugs, especially in the elderly, with multiple comorbidities. Exposition to a polypharmacy burden represents a favourable substrate for the onset of non-steroidal anti-inflammatory drug-induced deleterious effects. Cardiovascular and renal issues concerning the occurrence of myocardial infarction, atrial fibrillation, heart failure and arterial hypertension, as well as acute or chronic kidney damage, become critical for clinicians in their daily practice. We discuss current available knowledge regarding prostanoid physiology in vascular, cardiac and renal systems, pointing out potential negative non-steroidal anti-inflammatory drug-related issues in clinical practice.
WehlingM. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: Management and mitigation of risks and adverse effects. Eur J Clin Pharmacol2014; 70: 1159–1172.
2.
ZhouYBoudreauDMFreedmanAN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf2014; 23: 43–50.
3.
BrattwallMTuranIJakobssonJ. Musculoskeletal pain: Prescription of NSAID and weak opioid by primary health care physicians in Sweden 2004–2008 – a retrospective patient record review. J Pain Res2010; 3: 131–135.
4.
Osmed. The Medicines Utilisation Monitoring Centre. National report on medicines use in Italy. 2017. Rome: Italian Medicines Agency, 2018.
5.
KristensenKBKarlstadOMartikainenJE, et al.Nonaspirin nonsteroidal antiinflammatory drug use in the Nordic countries from a cardiovascular risk perspective, 2000–2016: A drug utilization study. Pharmacotherapy2019; 39: 150–160.
6.
SolomonDHHusniMEWolskiKE, et al.PRECISION Trial Investigators. Differences in safety of nonsteroidal antiinflammatory drugs in patients with osteoarthritis and patients with rheumatoid arthritis: A randomized clinical trial. Arthritis Rheumatol2018; 70: 537–546.
7.
FranceschiMScarcelliCNiroV, et al.Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: A prospective study of 1756 patients. Drug Saf2008; 31: 545–556.
8.
KeithSWMaioVDudashK, et al.A physician-focused intervention to reduce potentially inappropriate medication prescribing in older people: A 3-year, Italian, prospective, proof-of-concept study. Drugs Aging2013; 30: 119–127. .
9.
VargaSAlcuskyMKeithSW, et al.Hospitalization rates during potentially inappropriate medication use in a large population-based cohort of older adults. Br J Clin Pharmacol2017; 83: 2572–2580.
10.
NarumiyaSFitzgeraldGA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest2001; 108: 25–30.
11.
WoodwardDFJonesRLNarumiyaS. International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev2011; 63: 471–538.
12.
Lezoualc'hFFazalLLaudetteM, et al.Cyclic AMP sensor EPAC proteins and their role in cardiovascular function and disease. Circ Res2016; 118: 881–897.
13.
GrosserTFriesSFitzGeraldGA. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest2006; 116: 4–15.
14.
VaneJRBakhleYSBottingRM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol1998; 38: 97–120.
15.
KirkbyNSChanMVZaissAK, et al.Systematic study of constitutive cyclooxygenase-2 expression: Role of NF-κB and NFAT transcriptional pathways. Proc Natl Acad Sci U S A2016; 113: 434–439.
16.
HörlWH. Nonsteroidal anti-inflammatory drugs and the kidney. Pharmaceuticals (Basel)2010; 3: 2291–2321.
17.
RicciottiEYuYGrosserT, et al.COX-2, the dominant source of prostacyclin. Proc Natl Acad Sci U S A2013; 110: E183.
18.
KirkbyNSZaissAKUrquhartP, et al.LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression. PLoS One2013; 8: e69524.
19.
MurataTUshikubiFMatsuokaT, et al.Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature1997; 388: 678–682.
20.
ChengYAustinSCRoccaB, et al.Role of prostacyclin in the cardiovascular response to thromboxane A2. Science2002; 296: 539–541.
21.
FélétouMHuangYVanhouttePM. Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol2011; 164: 894–912.
22.
FabreJENguyenMAthirakulK, et al.Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest2001; 107: 603–610.
23.
KobayashiTTaharaYMatsumotoM, et al.Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest2004; 114: 784–794.
24.
LangenbachRMorhamSGTianoHF, et al.Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell1995; 83: 483–492.
25.
SzerafinTErdeiNFülöpT, et al.Increased cyclooxygenase-2 expression and prostaglandin-mediated dilation in coronary arterioles of patients with diabetes mellitus. Circ Res2006; 99: e12–e17.
26.
FanelliAGhisiDAprilePL, et al.Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: Latest evidence and clinical implications. Ther Adv Drug Saf2017; 8: 173–182.
27.
GhoshRAlajbegovicAGomesAV. NSAIDs and cardiovascular diseases: Role of reactive oxygen species. Oxid Med Cell Longev2015; 2015: 536962.
28.
KennedyCRZhangYBrandonS, et al.Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med1999; 5: 217–220.
29.
HerreraMYangTSparksMA, et al.Complex role for E-prostanoid 4 receptors in hypertension. J Am Heart Assoc2019; 8: e010745.
30.
MendezMLaPointeMC. PGE2-induced hypertrophy of cardiac myocytes involves EP4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation. Am J Physiol Heart Circ Physiol2005; 288: H2111–H2117.
31.
XiaoCYYuhkiKHaraA, et al.PGE2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation2004; 109: 2462–2468.
32.
HaraAYuhkiKFujinoT, et al.Augmented cardiac hypertrophy in response to pressure overload in mice lacking the prostaglandin I2 receptor. Circulation2005; 112: 84–92.
33.
WangDPatelVVRicciottiE, et al.Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc Natl Acad Sci USA2009; 106: 7548–7552.
34.
PatronoCDunnMJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int1987; 32: 1–12.
35.
SchnermannJBriggsJP. Tubular control of renin synthesis and secretion. Pflugers Arch2013; 465: 39–51.
36.
TheiligFCampeanVPaliegeA, et al.Epithelial COX-2 expression is not regulated by nitric oxide in rodent renal cortex. Hypertension2002; 39: 848–853.
37.
HarrisRCMcKannaJAAkaiY, et al.Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest1994; 94: 2504–2510.
38.
YangTEndoYHuangYG, et al.Renin expression in COX-2 knockout mice on normal or low-salt diets. Am J Physiol Renal Physiol2000; 279: F819–F825.
39.
KomhoffMJeckNDSeyberthHW, et al.Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome. Kidney Int2000; 58: 2420–2424.
40.
OlesenETFentonRA. Is there a role for PGE2 in urinary concentration?. J Am Soc Nephrol2013; 24: 169–178.
41.
PerazellaMA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol2009; 4: 1275–1283.
42.
TakahashiKSchreinerGFYamashitaK, et al.Predominant functional roles for thromboxane A2 and prostaglandin E2 during late nephrotoxic serum glomerulonephritis in the rat. J Clin Invest1990; 85: 1974–1982.
43.
BruneKPatrignaniP. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res2015; 8: 105–118.
44.
ChanTY. Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: Mechanisms, clinical significance, and avoidance. Ann Pharmacother1995; 29: 1274–1283.
45.
OuelletMPercivalMD. Mechanism of acetaminophen inhibition of cyclooxygenase isoforms. Arch Biochem Biophys 2001 15;387: 273–280.
46.
SorokinA. Nitric oxide synthase and cyclooxygenase pathways: A complex interplay in cellular signaling. Curr Med Chem2016; 23: 2559–2578.
47.
RodriguesAD. Impact of CYP2C9 genotype on pharmacokinetics: Are all cyclooxygenase inhibitors the same?. Drug Metab Dispos2005; 33: 1567–1575.
48.
McAlindonTEBannuruRRSullivanMC, et al.OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage2014; 22: 363–388.
49.
WheltonA. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med2001; 110: 33S–42S.
50.
ZhangXDonnanPTBellS, et al.Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: Systematic review and meta-analysis. BMC Nephrol2017; 18: 256.
51.
PlantingaLGrubbsVSarkarU, et al.Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States. Ann Fam Med2011; 9: 423.
52.
VegaJGoeckeHMéndezGP, et al.Nephrotic syndrome and acute tubular necrosis due to meloxicam use. Ren Fail2012; 34: 1344–1347.
53.
MarkowitzGSBombackASPerazellaMA. Drug-induced glomerular disease: Direct cellular injury. Clin J Am Soc Nephrol2015; 10: 1291–1299.
54.
MohammedEPStevensJM. Recurrence of Arthrotec-associated nephrotic syndrome with re-challenge. Clin Nephrol2000; 53: 483–485.
55.
PragaMSevillanoAAuñónP, et al.Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury. Nephrol Dial Transplant2015; 30: 1472–1479.
56.
De BroeMEElseviersMM. Over-the-counter analgesic use. J Am Soc Nephrol2009; 20: 2098–2103.
57.
NderituPDoosLJonesPW, et al.Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: A systematic review. Fam Pract2013; 30: 247–255.
58.
PernegerTVWheltonPKKlagMJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med1994; 331: 1675–1679.
59.
NdetanHEvansMWJrSingalAK, et al.Light to moderate drinking and therapeutic doses of acetaminophen: An assessment of risks for renal dysfunction. Prev Med Rep2018; 12: 253–258.
60.
AgodoaLYFrancisMEEggersPW. Association of analgesic use with prevalence of albuminuria and reduced GFR in US adults. Am J Kidney Dis2008; 51: 573–583.
61.
NissenSEYeomansNDSolomonDH, et al.PRECISION Trial Investigators. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med2016; 375: 2519–2529.
SnowdenSNelsonR. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. Cardiol Rev2011; 19: 184–191.
64.
IshiguroCFujitaTOmoriT, et al.Assessing the effects of non-steroidal anti-inflammatory drugs on antihypertensive drug therapy using post-marketing surveillance database. J Epidemiol2008; 18: 119–124.
65.
RuschitzkaFBorerJSKrumH, et al.Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: The PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur Heart J2017; 38: 3282–3292.
66.
ZanchettiAHanssonLLeonettiG, et al.Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. J Hypertens2002; 20: 1015–1022.
67.
SudanoIFlammerAJPériatD, et al.Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation2010; 122: 1789–1796.
68.
DawsonJFultonRMcInnesGT, et al.Acetaminophen use and change in blood pressure in a hypertensive population. J Hypertens2013; 31: 1485–1490.
69.
ChiamEWeinbergLBaileyM, et al.The haemodynamic effects of intravenous paracetamol (acetaminophen) in healthy volunteers: A double-blind, randomized, triple crossover trial. Br J Clin Pharmacol2016; 81: 605–612.
70.
LafranceJPMillerDR. Dispensed selective and nonselective nonsteroidal anti-inflammatory drugs and the risk of moderate to severe hyperkalemia: A nested case-control study. Am J Kidney Dis2012; 60: 82–89.
71.
NgJLMorganDJLohNK, et al.Life-threatening hypokalaemia associated with ibuprofen-induced renal tubular acidosis. Med J Aust2011; 194: 313–316.
72.
ClarkBAShannonRPRosaRM, et al.Increased susceptibility to thiazide-induced hyponatremia in the elderly. J Am Soc Nephrol1994; 5: 1106–1111.
73.
PatronoCPatrignaniPGarcía RodríguezLA. Cyclooxygenase-selective inhibition of prostanoid formation: Transducing biochemical selectivity into clinical read-outs. J Clin Invest2001; 108: 7–13.
74.
De CaterinaRRuigomezAGarcia RodriguezLA. Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. Arch Intern Med2010; 170: 1450–1455.
75.
SchmidtMChristiansenCFMehnertF, et al.Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: Population based case-control study. BMJ2011; 343: d3450.
76.
ChaoT-FLiuC-JChenS-J, et al.The association between the use of non-steroidal anti-inflammatory drugs and atrial fibrillation: A nationwide case-control study. Int J Cardiol2013; 168: 312–316.
77.
BäckMYinLIngelssonE. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur Heart J2012; 33: 1928–1933.
78.
Schjerning OlsenAMFosbølELPallisgaardJ, et al.NSAIDs are associated with increased risk of atrial fibrillation in patients with prior myocardial infarction: A nationwide study. Eur Heart J Cardiovasc Pharmacother2015; 1: 107–114.
79.
LiuGYanY-PZhengX-X, et al.Meta-analysis of nonsteroidal anti-inflammatory drug use and risk of atrial fibrillation. Am J Cardiol2014; 114: 1523–1529.
80.
KrijtheBPHeeringaJHofmanA, et al.Non-steroidal anti-inflammatory drugs and the risk of atrial fibrillation: A population-based follow-up study. BMJ Open2014; 4: e004059.
81.
SondergaardKBGislasonG. NSAIDs and cardiac arrest: Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: A nationwide case-time-control study. Eur Heart J2017; 38: 1788–1789.
82.
BombardierCLaineLReicinA, et al.VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med2000; 343: 1520–1528.
83.
BresalierRSSandlerRSQuanH, et al.Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med2005; 352: 1092–1102.
84.
LévesqueLEBrophyJMZhangB. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ2006; 174: 1563–1569.
85.
Schjerning OlsenAMFosbølELLindhardsenJ, et al.Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: A nationwide cohort study. Circulation2011; 123: 2226–2235.
86.
RossJSMadiganDKonstamMA, et al.Persistence of cardiovascular risk after rofecoxib discontinuation. Arch Intern Med2010; 170: 2035–2036.
87.
KearneyPMBaigentCGodwinJ, et al.Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ2006; 332: 1302–1308.
88.
BhalaNEmbersonJMerhiA, et al.Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet2013; 382: 769–779.
89.
García RodríguezLATacconelliSPatrignaniP. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol2008; 52: 1628–1636.
90.
StysTLawsonWESmaldoneGC, et al.Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure. Arch Intern Med2000; 160: 1409–1413.
91.
LatiniRTognoniGMaggioniAP, et al.Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: Systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol2000; 35: 1801–1807.
92.
BorghiCAmbrosioniENovoS, et al.SMILE-4 Working Party. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: Results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clin Cardiol2012; 35: 416–423.
93.
GislasonGHRasmussenJNAbildstromSZ, et al.Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med2009; 169: 141–149.
94.
ScottPAKingsleyGHScottDL. Non-steroidal anti-inflammatory drugs and cardiac failure: Meta-analyses of observational studies and randomised controlled trials. Eur J Heart Fail2008; 10: 1102–1107.
95.
ArfèAScottiLVaras-LorenzoC, et al.Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: Nested case-control study. BMJ2016; 354: i4857.
96.
Ahmetaj-ShalaBKirkbyNSKnowlesR, et al.Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: Novel explanation of cardiovascular side effects associated with anti-inflammatory drugs. Circulation2015; 131: 633–642.
97.
ReedGWAbdallahMSShaoM, et al.Effect of aspirin coadministration on the safety of celecoxib, naproxen, or ibuprofen. J Am Coll Cardiol2018; 71: 1741–1751.
OgataTIdenoYAkaiM, et al.Effects of glucosamine in patients with osteoarthritis of the knee: A systematic review and meta-analysis. Clin Rheumatol2018; 37: 2479–2487.
100.
BannuruRRSchmidCHKentDM, et al.Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: A systematic review and network meta-analysis. Ann Intern Med2015; 162: 46–54.
101.
DadaboJFramJJayabalanP. Noninterventional therapies for the management of knee osteoarthritis. J Knee Surg2019; 32: 46–54.
102.
DragosDGilcaMGamanL, et al.Phytomedicine in joint disorders. Nutrients2017; 9: e70.
103.
JonesPDalzielSRLamdinR, et al.Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. Cochrane Database Syst Rev2015; 7: CD007789.
104.
KötterTda CostaBRFässlerM, et al.Metamizole-associated adverse events: A systematic review and meta-analysis. PLoS One2015; 10: e0122918.
105.
HuberMAndersohnFSarganasG, et al.Metamizole-induced agranulocytosis revisited: Results from the prospective Berlin Case-Control Surveillance Study. Eur J Clin Pharmacol2015; 71: 219–227.
106.
FernandesLHagenKBBijlsmaJW, et al.EULAR recommendations for the nonpharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis2013; 72: 1125–1135.
107.
Floor-SchreuderingADe SmetPABuurmaH, et al.NSAID-antihypertensive drug interactions: Which outpatients are at risk for a rise in systolic blood pressure?. Eur J Prev Cardiol2015; 22: 91–99.
108.
US Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes, http://www.fda.gov/Drugs/DrugSafety/ucm451800.htm (2015, accessed 10 July 2018).
SchmidtMLambertsMOlsenAM, et al.Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: Review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J2016; 37: 1015–1023.
